| Mrs Liane Marie Wilt, OD | |
|
107 S Main St, Ada, OH 45810-1240 | |
| (419) 634-2921 | |
| (419) 634-9858 |
| Full Name | Mrs Liane Marie Wilt |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 21 Years |
| Location | 107 S Main St, Ada, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780722389 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 5442 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eyes On Main, Llc | 6709950991 | 4 |
| Village Vision Center, Inc. | 6800943325 | 3 |
News Archive
Scientists have proposed a new approach to preventing the proliferation of prostate tumor cells that are no longer responding to treatment. Prostate cancer can usually be cured via surgical removal of the tumor and/or the use of radiotherapy, but in one-fifth of cases, patients also require treatment with drugs to continue removing tumor cells. However, these drugs are only effective for up to three years, after which the cancer continues to develop.
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million.
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.
Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.
› Verified 3 days ago
| Provider Name | Eyes On Main, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477735538 PECOS PAC ID: 6709950991 Enrollment ID: O20080806000448 |
News Archive
Scientists have proposed a new approach to preventing the proliferation of prostate tumor cells that are no longer responding to treatment. Prostate cancer can usually be cured via surgical removal of the tumor and/or the use of radiotherapy, but in one-fifth of cases, patients also require treatment with drugs to continue removing tumor cells. However, these drugs are only effective for up to three years, after which the cancer continues to develop.
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million.
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.
Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.
› Verified 3 days ago
| Provider Name | Village Vision Center, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1730378373 PECOS PAC ID: 6800943325 Enrollment ID: O20090420000362 |
News Archive
Scientists have proposed a new approach to preventing the proliferation of prostate tumor cells that are no longer responding to treatment. Prostate cancer can usually be cured via surgical removal of the tumor and/or the use of radiotherapy, but in one-fifth of cases, patients also require treatment with drugs to continue removing tumor cells. However, these drugs are only effective for up to three years, after which the cancer continues to develop.
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million.
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.
Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Liane Marie Wilt, OD 730 Parkview Dr, Findlay, OH 45840-8639 Ph: (419) 420-7661 | Mrs Liane Marie Wilt, OD 107 S Main St, Ada, OH 45810-1240 Ph: (419) 634-2921 |
News Archive
Scientists have proposed a new approach to preventing the proliferation of prostate tumor cells that are no longer responding to treatment. Prostate cancer can usually be cured via surgical removal of the tumor and/or the use of radiotherapy, but in one-fifth of cases, patients also require treatment with drugs to continue removing tumor cells. However, these drugs are only effective for up to three years, after which the cancer continues to develop.
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million.
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.
Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.
› Verified 3 days ago
Dr. Duane L Wires, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 107 S Main St, Ada, OH 45810 Phone: 419-634-2921 Fax: 419-634-9858 | |
Village Vision Center, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 107 S Main St, Ada, OH 45810 Phone: 419-634-2921 Fax: 419-634-9858 |